康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02162 康诺亚-B

已收盘 11-22 16:08:13

38.200

-1.300

-3.29%

最高39.550	最低37.650	成交量77.40万
今开39.550	昨收39.500	日振幅4.81%
总市值106.86亿	流通市值106.86亿	总股本2.80亿
成交额2,959万	换手率0.28%	流通股本2.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"康诺亚-B","latestPrice":38.2,"timestamp":1732262893016,"preClose":39.5,"halted":0,"volume":774027,"delay":0,"floatShares":279735566,"shares":279735566,"eps":-1.4747591,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.3,"latestTime":"11-22 16:08:13","open":39.55,"high":39.55,"low":37.65,"amount":29591224,"amplitude":0.048101,"askPrice":38.2,"askSize":1000,"bidPrice":38,"bidSize":40500,"shortable":3,"etf":0,"ttmEps":-3.0540022860056197,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"listingDate":1625673600000,"adjPreClose":39.5,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":0.730283,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"2485338222","title":"康诺亚-B11月22日主力资金流出69万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2485338222","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485338222?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:16","pubTimestamp":1732263419,"startTime":"0","endTime":"0","summary":"11月22日, 康诺亚-B股价跌3.29%，报收38.20元，成交金额2959万元，换手率0.28%，振幅4.81%，量比0.73。康诺亚-B今日主力资金净流出69万元，连续3日净流出，上一交易日主力净流出76万元，今日环比减少9.21%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为63.64%，平均跌幅为3.32%。该股近5个交易日下跌1.40%，主力资金累计净流入97万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入832万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122161759a24d6641&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122161759a24d6641&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02162","BK1587","BK1583","BK1574"],"gpt_icon":0},{"id":"2484313908","title":"港股异动 | 康诺亚-B(02162)涨超7% BCMA/CD3双抗通过NewCo出海 款项超6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484313908","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484313908?lang=zh_cn&edition=full","pubTime":"2024-11-20 11:24","pubTimestamp":1732073058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B(02162)涨超7%，截至发稿，涨7.05%，报41港元，成交额1993.62万港元。消息面上，康诺亚生物近日宣布BMCA/CD3双抗通过NewCo方式出海，将CM336的大中华区外全球权益授权给PML。根据协议，PML支付1600万美元预付款和近期付款，6.1亿美元里程碑金额，以及一定比例的销售分成。康诺亚将持有Ouro Medicines的少数股权。华泰证券研报指出，考虑TCE治疗自免适应症已初获验证，且对手方在既往交易中展现出对自免领域的深入理解和强大的转化医学能力，看好CM336的全球商业价值。维持“买入”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","BK1161","BK1587","02162"],"gpt_icon":0},{"id":"2484381211","title":"康诺亚-B(02162)上涨5.22%，报40.3元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484381211","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484381211?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:13","pubTimestamp":1732068806,"startTime":"0","endTime":"0","summary":"11月20日，康诺亚-B(02162)盘中上涨5.22%，截至10:13，报40.3元/股，成交1162.57万元。康诺亚生物医药科技有限公司专注于研发高质量、可负担的创新疗法，主要业务包括分子发现、工艺开发、转化医学、临床开发到商业化生产药品开发全周期。公司自主研发的一类创新药逾30项，其中9项已进入不同阶段临床研发，多项位于中国第一，世界前三，包含一项世界首创ADC新药，两项获得国家“十三五”“重大新药创制”科技重大专项支持。截至2024年中报，康诺亚-B营业总收入5468.2万元、净利润-3.37亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/20101345475717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1574","BK1161","BK1587","02162"],"gpt_icon":0},{"id":"2484138265","title":"康诺亚-B盘中异动 早盘股价大涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484138265","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484138265?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:13","pubTimestamp":1732068806,"startTime":"0","endTime":"0","summary":"2024年11月20日早盘10时13分，康诺亚-B股票出现异动，股价大幅上涨5.22%。资金方面，该股资金流入541.322万港元，流出464.752万港元。康诺亚-B股票所在的生物技术行业中，整体涨幅为1.21%。作为回报，康诺亚将获得1600万美元首付款和近期付款，同时获得PML母公司Ouro Medicines的少数股权作为对价的一部分。就许可协议而言，PML与康诺亚将订立临床供应协议，据此，PML将向康诺亚采购CM336药品的临床供应。11月18日，康诺亚股价下挫，下午三点股价跌4.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120101327971a792c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120101327971a792c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1161","BK1574","BK1583","02162"],"gpt_icon":0},{"id":"2484099956","title":"康诺亚-B11月19日获主力加仓379万元 环比增加340.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484099956","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484099956?lang=zh_cn&edition=full","pubTime":"2024-11-19 16:16","pubTimestamp":1732004188,"startTime":"0","endTime":"0","summary":"11月19日, 康诺亚-B股价涨1.86%，报收38.30元，成交金额3038万元，换手率0.29%，振幅4.12%，量比0.67。康诺亚-B今日主力资金净流入379万元，连续4日净流入，上一交易日主力净流入86万元，今日环比增加340.70%。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为50.00%，平均涨幅为3.15%。该股近5个交易日下跌12.13%，主力资金累计净流入303万元；近20日主力资金累计净流入2021万元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119161656a24523af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119161656a24523af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02162","BK1574","BK1587","BK1161","BK1583"],"gpt_icon":0},{"id":"2484750961","title":"一周内官宣4笔BD交易！双抗新药赛道火爆，跨国药企砸百亿在华“扫货”","url":"https://stock-news.laohu8.com/highlight/detail?id=2484750961","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484750961?lang=zh_cn&edition=full","pubTime":"2024-11-19 14:17","pubTimestamp":1731997033,"startTime":"0","endTime":"0","summary":"本文来源：时代财经 作者：李傲华双抗赛道日渐升温。11月18日，橙帆医药宣布与Avenzo Therapeutics达成一项全球战略合作协议，橙帆医药将授予Avenzo在全球范围内（不包括大中华区）开发、生产和商业化Nectin4/TROP2双特异性抗体偶联药物（ADC），同时保留在大中华区的相关权益。根据约定，橙帆医药可以获得5000万美元的首付...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OGXNPipjng5N0EEVqCMMar7oEn1NEUUoSMX0OgZcn7fE0AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OGXNPipjng5N0EEVqCMMar7oEn1NEUUoSMX0OgZcn7fE0AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241119A052YN00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241119A052YN00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU1057294990.SGD","LU0985320562.USD","SG9999013999.USD","LU0417516571.SGD","LU2461242641.AUD","BK4588","PML","LU1066053197.SGD","09939","LU0289739699.SGD","LU0106261372.USD","GSK","LU1934455863.HKD","BK4080","GSK.UK","LU1061106388.HKD","LU0203347892.USD","LU1116320901.HKD","MRK","LU0053671581.USD","BK4007","SG9999014542.SGD","09926","LU0266013472.USD","SGXZ57979304.SGD","LU1116320737.USD","SG9999015341.SGD","BK4211","LU2112291526.USD","LU2023250504.SGD","IE0002141913.USD","BMS","L","LU0965509010.AUD","IE00BJJMRZ35.SGD","ADC","SG9999001176.SGD","IE00BLSP4239.USD","BK4231","LU1023059063.AUD","BK4534","HR","IE00B1BXHZ80.USD","BK4107","ITT","02162","SG9999001176.USD","LU1934455194.USD","SG9999014559.SGD","PFS"],"gpt_icon":0},{"id":"2484100356","title":"康诺亚-B11月18日主力资金流入86万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2484100356","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484100356?lang=zh_cn&edition=full","pubTime":"2024-11-18 16:16","pubTimestamp":1731917779,"startTime":"0","endTime":"0","summary":"11月18日, 康诺亚-B股价跌4.45%，报收37.60元，成交金额4877万元，换手率0.46%，振幅7.12%，量比1.20。康诺亚-B今日主力资金净流入86万元，连续3日净流入，上一交易日主力净流入54万元，今日环比增加59.26%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为55.56%，平均涨幅为3.74%。该股近5个交易日下跌15.42%，主力资金累计净流出76万元；近20日主力资金累计净流入2109万元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118161704a2425797&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118161704a2425797&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1587","02162","BK1583"],"gpt_icon":0},{"id":"2484660117","title":"康诺亚-B(02162)下跌5.21%，报37.3元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484660117","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484660117?lang=zh_cn&edition=full","pubTime":"2024-11-18 10:44","pubTimestamp":1731897851,"startTime":"0","endTime":"0","summary":"11月18日，康诺亚-B(02162)盘中下跌5.21%，截至10:44，报37.3元/股，成交1625.97万元。康诺亚生物医药科技有限公司专注于研发高质量、可负担的创新疗法，主要业务包括分子发现、工艺开发、转化医学、临床开发到商业化生产药品开发全周期。公司自主研发的一类创新药逾30项，其中9项已进入不同阶段临床研发，多项位于中国第一，世界前三，包含一项世界首创ADC新药，两项获得国家“十三五”“重大新药创制”科技重大专项支持。截至2024年中报，康诺亚-B营业总收入5468.2万元、净利润-3.37亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18104445388043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","02162","BK1587","BK1583","BK1161"],"gpt_icon":0},{"id":"2484698287","title":"康诺亚-B盘中异动 股价大跌5.21%报37.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484698287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484698287?lang=zh_cn&edition=full","pubTime":"2024-11-18 10:44","pubTimestamp":1731897849,"startTime":"0","endTime":"0","summary":"2024年11月18日早盘10时44分，康诺亚-B股票出现异动，股价快速跳水5.21%。截至发稿，该股报37.300港元/股，成交量42.7万股，换手率0.15%，振幅6.61%。资金方面，该股资金流入544.038万港元，流出714.615万港元。康诺亚-B股票所在的生物技术行业中，整体跌幅为0.71%。其相关个股中，华康生物医学、中国抗体-B、贝康医疗-B涨幅较大，振幅较大的相关个股有正大企业国际、百奥赛图-B、荃信生物-B，振幅分别为15.43%、14.59%、14.17%。该公司主要在中国国内和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111810440998e431eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111810440998e431eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02162","BK1583","BK1587","BK1574"],"gpt_icon":0},{"id":"2484664806","title":"6.26亿美元！康诺亚签下出海大单","url":"https://stock-news.laohu8.com/highlight/detail?id=2484664806","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484664806?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:31","pubTimestamp":1731893515,"startTime":"0","endTime":"0","summary":"11月17日，康诺亚生物宣布与PlatinaMedicinesLtd已订立独家许可协议（许可协议）。康诺亚将收取1600万美元的首付款和近期付款，在达成若干临床、监管及商业里程碑后，康诺亚可收取最多6.1亿美元的额外付款，并且亦有权从PML收取CM336及相关产品销售净额的分层特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411183242168234.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411183242168234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1574","BK1587","02162","BK1161"],"gpt_icon":0},{"id":"2484066818","title":"智通港股早知道 | 特朗普团队拟取消购买电动汽车税收优惠 市值管理新规落地：明确七种市值管理手段","url":"https://stock-news.laohu8.com/highlight/detail?id=2484066818","media":"智通财经","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484066818?lang=zh_cn&edition=full","pubTime":"2024-11-18 07:48","pubTimestamp":1731887291,"startTime":"0","endTime":"0","summary":"市值管理新规落地：明确七种市值管理手段 两类公司有特殊要求 上市公司市值管理新规落地实施。特朗普团队拟取消购买电动汽车税收优惠据媒体报道，美国新当选总统特朗普的过渡团队正计划取消购买电动汽车的7500美元消费者税收抵免，作为更广泛的税制改革立法的一部分。上周末美股电动汽车板块大幅下挫。作为回报，集团将收取1600万美元的首付款和近期付款，同时收取Ouro Medicines, LLC的少数股权作为对价的一部分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999001093.SGD","01877","LU0648948544.HKD","01763","LU1981816686.USD","LU0384037296.USD","LU1960683339.HKD","LU1961090484.USD","LU0577902454.USD","BK1575","HSTECH","LU2257852520.SGD","89988","LU0251144936.SGD","LU1993786604.SGD","LU0211977185.USD","LU0140636845.USD","LU0868486357.SGD","LU0228659784.USD","IE00BMPRXN33.USD","LU0516423174.USD","LU1720051108.HKD","LU1720051017.SGD","LU2357305700.SGD","LU0819121731.USD","LU0516423091.SGD","SG9999002463.SGD","LU0488056044.USD","LU1568876335.HKD","LU0149721374.USD","BABA","06855","LU0541502299.USD","LU1224444064.USD","LU0865486749.SGD","LU0231483743.USD","LU0831103253.SGD","LU0737861772.HKD","LU2097828805.USD","LU0054237671.USD","YANG","HSCEI","02162","01164","LU0348788117.USD","LU1719994722.HKD","HBBD.SI","LU1642822792.SGD","09988"],"gpt_icon":1},{"id":"2484682146","title":"康诺亚(02162.HK)授出CM336独家权利  收1,600万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2484682146","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484682146?lang=zh_cn&edition=full","pubTime":"2024-11-17 20:00","pubTimestamp":1731844800,"startTime":"0","endTime":"0","summary":"康诺亚－Ｂ(02162.HK) 公布，与Platina Medicines Ltd“PML”订立独家许可协议，据此，公司授予PML在全球(不包括中国、香港、澳门及台湾)开发、生产及商业化CM336的独家权利。CM336为公司自主开发的双特异性抗体。作为回报，集团将收取1,600万美元的首付款和近期付款，同时收取Ouro Medicines的少数股权作为对价的一部分。Ouro Medicines为PML的母公司，持有PML的全部股权。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-15 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210629113202608_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210629113202608_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397204/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02162","BK1574","BK1587","BK1161","BK1583"],"gpt_icon":0},{"id":"2484612682","title":"康诺亚全资附属公司签独家许可协议 预计可获最多6.1亿美元额外付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2484612682","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484612682?lang=zh_cn&edition=full","pubTime":"2024-11-17 19:35","pubTimestamp":1731843317,"startTime":"0","endTime":"0","summary":"财中社11月17日电康诺亚-B（02162）发布自愿性公告，宣布公司的全资附属公司成都康诺亚与PlatinaMedicinesLtd（PML）签署了独家许可协议。该协议赋予PML在全球（不包括中国大陆、香港、澳门及台湾）开发、生产及商业化CM336的独家权利。CM336为公司自主开发的双特异性抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411173241795985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","BK1587","BK1583","02162"],"gpt_icon":0},{"id":"2484686944","title":"康诺亚-B(02162)：与Platina Medicines Ltd订立CM336独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2484686944","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484686944?lang=zh_cn&edition=full","pubTime":"2024-11-17 18:11","pubTimestamp":1731838285,"startTime":"0","endTime":"0","summary":"康诺亚-B(02162)发布公告，于2024年11月17日，康诺亚生物医药科技(成...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_6.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_6.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02162","BK1587","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2483738558","title":"多种模式并驾齐驱 创新药出海捷报频传","url":"https://stock-news.laohu8.com/highlight/detail?id=2483738558","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483738558?lang=zh_cn&edition=full","pubTime":"2024-11-16 08:29","pubTimestamp":1731716986,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","LU0208291251.USD","LU1169590202.USD","LU1917777945.USD","LU0289739699.SGD","159992","LU1291159041.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU1057294990.SGD","LU1066053197.SGD","SG9999002232.USD","BK0060","LU0265550946.USD","161726","BK4534","LU1093756325.SGD","PD","LU0070302665.USD","BK4550","LU1064130708.USD","LU1989772840.SGD","02162","LU0985320562.USD","159938","SG9999001440.SGD","LU2106854487.HKD","SG9999014575.USD","BK1583","IE00BN8TJ469.HKD","BK0196","BK1574","LU2361044865.SGD","SG9999002224.SGD","LU1169589451.USD","LU2089984988.USD","BK0188","LU2023250504.SGD","600276","LU0203345920.USD","LU1066051225.USD","LU1983299246.USD","06978","SG9999014559.SGD","399441","LU0266013472.USD","MRK","09939","LU2112291526.USD"],"gpt_icon":0},{"id":"2483314825","title":"康诺亚-B(02162)下跌5.07%，报38.35元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483314825","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483314825?lang=zh_cn&edition=full","pubTime":"2024-11-15 15:09","pubTimestamp":1731654557,"startTime":"0","endTime":"0","summary":"11月15日，康诺亚-B(02162)盘中下跌5.07%，截至15:09，报38.35元/股，成交2851.15万元。康诺亚生物医药科技有限公司专注于研发高质量、可负担的创新疗法，主要业务包括分子发现、工艺开发、转化医学、临床开发到商业化生产药品开发全周期。公司自主研发的一类创新药逾30项，其中9项已进入不同阶段临床研发，多项位于中国第一，世界前三，包含一项世界首创ADC新药，两项获得国家“十三五”“重大新药创制”科技重大专项支持。截至2024年中报，康诺亚-B营业总收入5468.2万元、净利润-3.37亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/15150945332940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02162","BK1574","BK1583","BK1587","BK1161"],"gpt_icon":0},{"id":"2483314889","title":"康诺亚-B盘中异动 股价大跌5.07%报38.350港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483314889","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483314889?lang=zh_cn&edition=full","pubTime":"2024-11-15 15:08","pubTimestamp":1731654536,"startTime":"0","endTime":"0","summary":"2024年11月15日下午盘15时08分，康诺亚-B股票出现波动，股价大幅下挫5.07%。截至发稿，该股报38.350港元/股，成交量69.95万股，换手率0.25%，振幅8.04%。资金方面，该股资金流入992.445万港元，流出1407.41万港元。康诺亚-B股票所在的生物技术行业中，整体跌幅为0.39%。其相关个股中，永泰生物-B、北海康成-B、迈博药业-B涨幅较大，振幅较大的相关个股有北海康成-B、荃信生物-B、晶泰科技，振幅分别为25.64%、24.62%、22.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115150856971a6c1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115150856971a6c1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02162","BK1161","BK1574","BK1587","BK1583"],"gpt_icon":0},{"id":"2483090686","title":"康诺亚-B(02162)下跌5.03%，报41.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483090686","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483090686?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:55","pubTimestamp":1731462926,"startTime":"0","endTime":"0","summary":"11月13日，康诺亚-B(02162)盘中下跌5.03%，截至09:55，报41.5元/股，成交1814.12万元。康诺亚生物医药科技有限公司专注于研发高质量、可负担的创新疗法，主要业务包括分子发现、工艺开发、转化医学、临床开发到商业化生产药品开发全周期。公司自主研发的一类创新药逾30项，其中9项已进入不同阶段临床研发，多项位于中国第一，世界前三，包含一项世界首创ADC新药，两项获得国家“十三五”“重大新药创制”科技重大专项支持。截至2024年中报，康诺亚-B营业总收入5468.2万元、净利润-3.37亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13095545230495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1587","BK1583","02162","BK1161"],"gpt_icon":0},{"id":"2483013880","title":"康诺亚-B盘中异动 急速下挫5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483013880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483013880?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:55","pubTimestamp":1731462918,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘09时55分，康诺亚-B股票出现异动，股价大幅下跌5.03%。截至发稿，该股报41.500港元/股，成交量42.9174万股，换手率0.15%，振幅6.98%。机构评级方面，在所有9家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。康诺亚-B股票所在的生物技术行业中，整体跌幅为1.75%。康诺亚-B公司简介：康诺亚生物医药科技有限公司是一家生物科技公司,专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113095518a23202b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113095518a23202b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02162","BK1587","BK1574","BK1583"],"gpt_icon":0},{"id":"2481443071","title":"康诺亚-B11月08日获主力加仓491万元 环比增加882.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481443071","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481443071?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:17","pubTimestamp":1731053825,"startTime":"0","endTime":"0","summary":"11月08日, 康诺亚-B股价涨3.59%，报收44.70元，成交金额6842万元，换手率0.55%，振幅3.94%，量比1.59。康诺亚-B今日主力资金净流入491万元，连续3日净流入，上一交易日主力净流入50万元，今日环比增加882.00%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为55.56%，平均涨幅为3.74%。该股近5个交易日上涨2.41%，主力资金累计净流入761万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入3733万元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108161747abace926&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108161747abace926&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","BK1161","BK1587","02162"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.1053},{"period":"3month","weight":0.2191},{"period":"6month","weight":0.1567},{"period":"1year","weight":-0.2411},{"period":"ytd","weight":-0.1955}],"compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":-0.0438},{"period":"3month","weight":0.1129},{"period":"6month","weight":0.0533},{"period":"1year","weight":0.1052},{"period":"ytd","weight":0.1498}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Keymed Biosciences Inc是一家中国生物科技公司。该公司专注于自主发现及开发创新生物疗法以满足自体免疫及肿瘤治疗领域中未获满足的医疗需求。该公司已掌握内部药物发现及开发技术，其中包括构成其创新抗体发现平台及自有新型T细胞重定向(nTCE)双特异性抗体平台的技术。该公司还建立了涵盖生物药开发的关键功能的全面一体化平台。该公司主要产品包括CM310、CM326以及CMG901等。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.102216},{"month":2,"riseRate":0.666667,"avgChangeRate":0.052845},{"month":3,"riseRate":0,"avgChangeRate":-0.111304},{"month":4,"riseRate":1,"avgChangeRate":0.048679},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.125967},{"month":6,"riseRate":1,"avgChangeRate":0.150041},{"month":7,"riseRate":0.333333,"avgChangeRate":0.066538},{"month":8,"riseRate":0.5,"avgChangeRate":0.01599},{"month":9,"riseRate":0.75,"avgChangeRate":0.035232},{"month":10,"riseRate":0.5,"avgChangeRate":0.051059},{"month":11,"riseRate":0.5,"avgChangeRate":0.055318},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.129089}],"exchange":"SEHK","name":"康诺亚-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康诺亚-B,02162,康诺亚-B股票,康诺亚-B股票老虎,康诺亚-B股票老虎国际,康诺亚-B行情,康诺亚-B股票行情,康诺亚-B股价,康诺亚-B股市,康诺亚-B股票价格,康诺亚-B股票交易,康诺亚-B股票购买,康诺亚-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}